Similarly, in cardiovascular diseases, targeting PCSK9 lowers cholesterol levels, while NLRP3 knockout reduces myocardial inflammation, improving atherosclerosis and decreasing cardiovascular event risk (Makhmudova et al., 2024). Here, PCSK9 is linked to cardiovascular disorder.